ArticleAnatolian journal of cardiology2025
Effects of Cardiac Rehabilitation Exercise Plus Sacubitril Valsartan Sodium on Cardiac Function, Lung Function, and Quality of Life in Patients with Chronic Heart Failure.
Article in Anatolian journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulatory Effects of Clopidogrel on Vascular Response in the Human Internal Mammary Artery: An In Vitro Study.Anatolian journal of cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo explore the impacts of cardiac rehabilitation exercise plus sacubitril valsartan sodium on cardiac function, lung function, and quality of life in chronic heart failure (CHF) patients.
methodsOne hundred and forty-six CHF patients admitted to the hospital from January 2023 to December 2024 were chosen and divided into a control group (conventional treatment + sacubitril valsartan sodium) and a study group (conventional treatment + sacubitril valsartan sodium + cardiac rehabilitation exercise).
resultsThe total effective rate of the study group was higher when comparing with the control group (P < .05). The study group had higher left ventricular ejection fraction level as well as lower left ventricular end-systolic diameter, left ventricular end-diastolic diameter, and N-terminal pro B-type natriuretic peptide levels when comparing with the control group after 3 months of intervention (P < .01). The study group had higher forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC levels when comparing with the control group following 3 months of intervention (P < .01). The study group had higher SpO2, PaO2, and PaO2/FiO2 levels after 3 months of intervention (P < .01). The study group had longer 6-minute walking test after 3 months of intervention (P < .01). The study group had lower MLHFQ score when comparing with the control group after 3 months of intervention (P < .01). The rate of rehospitalization and incidence of major adverse cardiovascular event (MACE) in the study group were lower than in the control group (P < .05).
conclusionCardiac rehabilitation exercise combined with sacubitril valsartan sodium is effective in treating CHF patients, which improves cardiac function, lung function and blood gas levels, promotes exercise endurance and quality of life, and reduces the rehospitalization rate and MACE incidence in CHF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.